Aridis Pharmaceuticals, Inc. (OTCPK: ARDS)

About Aridis Pharmaceuticals, Inc.

Aridis Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies, specifically employing fully human monoclonal antibodies (mAbs) to address severe, life-threatening infections. Their lead product candidate, AR-301, a fully human IgG1 mAb, is currently in pivotal Phase III trials for treating lung infections caused by Staphylococcus aureus alpha toxin. Also in their pipeline is AR-320, another fully human IgG1 monoclonal antibody designed to target S. aureus alpha toxin, aiming to treat infections stemming from both methicillin-resistant (MRSA) and methicillin-susceptible S. aureus. The company's developmental efforts extend to AR-105, a fully human IgG1 mAb in Phase II trials, which is being developed to combat the gram-negative bacterium P. aeruginosa. Furthermore, AR-101, a human IgM mAb, is undergoing Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) specifically linked to P. aeruginosa serotype O11. In earlier stages, AR-401 is in preclinical development to address infections caused by Acinetobacter baumannii, and AR-201, a fully human IgG1 mAb, is in a preclinical program targeting respiratory syncytial virus. AR-501, an anti-infective therapy, is currently in Phase I/IIa clinical trials for managing chronic lung infections in patients with cystic fibrosis. Additionally, Aridis is developing AR-712 and AR-701, a combination of two fully human IgG1 mAbs, which is in Phase I/II clinical trials for treating mild to moderate COVID-19 in non-hospitalized individuals. Aridis Pharmaceuticals, Inc. was established in 2003 and is headquartered in Los Gatos, California.

ISIN

US0403341045

Founded

2003

Listed since

Aug 14, 2018

Exchange

Pink Sheets LLC

Currency

USD